Global Search

Hide Filters

Showing 114 results

Novartis 2020 Financial Results
Media Release / Sep 21, 2022

Novartis and the pan-Canadian Pharmaceutical Alliance (pCPA) conclude negotiations for Luxturna®, a gene therapy for previously untreatable inherited vision loss¹

Luxturna® (voretigene neparvovec) is a one-time gene therapy that provides healthy copies of the RPE65 gene for retinal cells that are lacking the normally functioning gene1 Dorval, QC, September…
Strategy
Terms of Use